Abstract: Lung cancerYrelated mortality is the most common cause of cancer death worldwide. Detecting lung cancer at an earlier stage and, ideally, predicting who will develop the disease and particularly the most aggressive forms of cancer are the biggest challenge. MicroRNAs (miRNAs) are short, noncoding RNA molecules with regulatory function on protein-coding genes. Because of their fundamental role in development and differentiation, their involvement in the biological mechanisms underlying tumorigenesis, as well as their low complexity, stability, and easy detection, they represent a promising class of tissue-and bloodbased biomarkers of cancer. We summarize the current literature on the use of microRNAs as diagnostic and prognostic tools in lung cancer and discuss the relevant clinical implications of these findings.
CONSIDERATIONS ON PREVIOUS RESEARCH INVOLVING IMAGING MODALITIES AND BIOMARKERS
These considerations call for effective secondary preventive measures for lung cancer based both on the use of refined imaging technologies and on the development of validated tissue and blood biomarkers.
Scientific research has recently focused on methods to detect lung cancer at an earlier stage. Being lower stage at diagnosis associated with significantly higher 5-year survival rate, imaging via low-dose computed tomography (LDCT) scanning is now being actively evaluated as a screening tool for early detection of lung cancer in high-risk patients. At present, the real efficacy of lung cancer screening in heavy smokers by spiral CT remains a controversial issue. 4, 5 The observational studies published so far have reported an up to threefold increase in the number of lung cancer diagnoses, without major decrease in the number of advanced cancers or reduction of mortality in smokers. 6 The preliminary results of a randomized spiral CT screening trial (DANTE) did not show significant effect in mortality reduction. 7 Conversely, the recent results of the largest randomized National Lung Screening Trial 8 showed a 7% reduction in all-cause mortality and j20% in lung cancerYspecific mortality in the spiral CTYscreened arm compared with annual chest x-rays monitoring; however, before CT screening can be offered to millions of individuals worldwide, a number of questions have to be answered: best selection of high-risk individuals, frequency and duration of screening, efficacy in current versus former smokers, cost and adverse effects related to radiologic exposure, and unnecessary invasive diagnostic procedures.
The issue of overdiagnosis of benign/indolent pulmonary lesions, which is intrinsic in screening trials, makes noninvasive biomarkers a desperate need to help differentiate malignant lesions from the benign, which are detected by the sensitive LDCT, and to detect tumor's existence before visualization is possible.
For the earliest and accurate diagnosis, it is necessary to find noninvasive cancer biomarkers to monitor molecular differences in tumors, which may assist in the selection of the best possible treatment for individual cancer patients.
Validated circulating biomarkers in plasma/serum could potentially represent the criterion standard for a noninvasive routine clinical application. Blood represents an ideal compartment to develop noninvasive diagnostics for lung cancer because of its rich content of diverse cellular and molecular elements, which provide information on the health status of an individual. Blood samples can be easily and inexpensively collected by noninvasive procedures throughout large clinical trials. However, to date, there are no validated biomarkers in blood and body fluids for detection or prognosis of lung disease, and the sensitivity and specificity of biomarkers generated so far are inadequate for a clinical application.
A conceptual reason for this failure could be related to the fact that past approaches for biomarker discovery were focused mainly on the identification of the early molecular events known to be involved in multistep tumorigenesis of lung cancer, according to the traditional lung cancer natural history model. At present, discovery of biomarkers in blood and biological fluids still relies on those genetic and epigenetic changes identified in both lung cancers and precancerous lesions because the classic natural history model of lung cancer assumes that early-stage cancers are the precursor lesion of advanced and fatal lung disease. Nonetheless, these biological/molecular changes are not necessarily the same that predispose and prompt tumor development and progression. At present, the most promising biomarkers, which should be able to predict tumor development and aggressiveness, are those produced not only from (pre)cancerous cells but also from tumor microenvironment, the host response, and their dynamic interaction (Fig. 1) .
In a recent study, 9 for the first time, we reported the results at 10 years of annual CT screening, as well as a new approach to early detection with molecular markers. Our data show that CT screening detects a high proportion of early-stage tumors with excellent survival during the first 2 years, whereas as the screening progresses, the frequency of late-stage tumors increases. These ''early advanced'' cancers have a poor prognosis similar to the clinically detected (or symptomatic) advanced cancers. 5 These findings seem to indicate that not all aggressive lung tumors arise from identifiable slow-growing precursors and indicate a bipartite biological model of lung cancer, with one indolent and one aggressive type from the very beginning, rather than one common initial type, which may turn into aggressive over time. 10 In this context, the identification of novel and reliable biomarkers able to identify tumors in a preclinical phase and to track the different aggressiveness of lung tumors, including the early metastatic cancers or even the small lesions with aggressive potential, is of paramount importance.
MicroRNAs AS BIOMARKERS IN LUNG CANCER
MicroRNAs (miRNAs) are small, noncoding, endogenous single-stranded ribonucleic acids with regulatory functions that are involved in tuning of many important pathways, including developmental and oncogenic pathways. MicroRNAs are evolutionary conserved and tissue specific and play a critical role in development and differentiation processes of tissues and organs, and their expression is altered in various disease states and cancer. 11 The biological and clinical relevance of miRNA expression patterns has been established first in human B-cell chronic lymphocytic leukemia, 12 and changes in miRNA expression levels have been afterward detected in all major types of solid tumors, including lung cancer.
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PROGNOSTIC SIGNIFICANCE OF MIRNAS IN NON-SMALL CELL LUNG CANCER TISSUES
Recent studies have demonstrated the critical role of miRNAs in lung cancer pathogenesis and their potential as biomarkers for lung cancer risk stratification, outcome prediction, and classification of histologic subtypes.
In 2004, Takamizawa and coworkers 15 were the first to pinpoint the prognostic value of miRNAs by showing that let-7 expression was reduced in lung cancer and that lung cancer patients with low let-7 expression levels have a significantly shorter survival after potentially curative resection. This study represents the first report of reduced expression of let-7 and the potential clinical and biological effects of such an miRNA alteration in lung cancer.
In March 2005, the group of F. J. Slack reported for the first time an miR target interaction with relevance to lung cancer. Using the Caenorhabditis elegans model, they showed that let-7 targets let-60, encoding the C. elegans ortholog of human oncogene RAS. Accordingly, decreased let-7 expression and increased RAS protein levels were detected in lung tumor samples. 16 A critical role for let-7 family miRNAs as tumor suppressors in lung cancer is supported also by the finding of a single nucleotide polymorphism (SNP) in let-7 complementary site 6 of the K-RAS mRNA 3 ¶ untranslated region (UTR) that regulates entry into the S phase of the cell cycle and is significantly associated with increased risk for non-small cell lung cancer (NSCLC) among moderate smokers. 17 The first large genome-wide expression analysis of miRNAs showed a significantly different profile among 104 pairs of primary lung cancers and noncancerous lung tissues. The global expression profile of miRNAs could identify 5 miRNAs (hsa-mir-155, has-mir-17-3p, hsa-let-7a-2, hsa-mir-145, and hsa-mir-21) that were associated with adenocarcinoma patient survival. Of interest, the clinical importance of 2 outcome-predictive miRNAs (high hsa-mir-155 and low hsa-let-7a-2) was cross-validated using an independent cohort of stage I adenocarcinoma by quantitative real-time polymerase chain reaction analysis (q-RT-PCR), a technology easily transferrable to a clinical laboratory. 18, 19 Using q-RT-PCRYbased analysis, a 5-miRNA signature, including reduced let-7 expression, revealed to be an independent predictor of cancer relapse and survival of 122 NSCLC patients. 19 The study of large patient cohorts led to conflicting results. In fact, the expression levels of a panel of relevant miRNAs, some of them already reported in the previously mentioned studies such as let-7a, mir-155, mir-21, mir-29b, and mir-34 family, determined by q-RT-PCR in formalin-fixed paraffin-embedded sections from 639 patients belonging to International Adjuvant Lung Cancer Trial, the largest randomized study of adjuvant chemotherapy in NSCLC patients, did not find significant association between any of the tested miRNAs and survival, concluding that miRNA expression patterns examined were neither predictive nor prognostic in this large patient cohort. 20 On the contrary, Saito et al 21 measured by q-RT-PCR the expression of miR-21, miR-17, and miR-155 in tissues from 317 NSCLC patients who originated from 3 different countries (Maryland, Norway, and Japan) and evaluated associations of miRNA expression with cancer-specific mortality and disease-free survival. They reported that increased miR-21 expression was associated with disease progression and survival in stage I lung cancer and concluded that miR-21 could serve as a therapeutic target or earlystage prognostic biomarker for lung adenocarcinoma. 23 analyzed miRNA expression profiles in 23 NSCLC patients by using an miRNA microarray platform and showed that mir-451 was the most down-regulated and correlated with pathological stage, metastatic disease, and shorter overall survival of the patients.
Selected miRNA families have been found to be good biomarkers, such as miR-34 family, whose downregulation was associated in a multivariate analysis with higher risk of relapse in 70 surgically resected NSCLC patients 24 and mir-221, mir-222, miR-210 that were overexpressed in aggressive, late stages NSCLC patients. 25, 26 Two large studies addressed the issue of prognostic miRNAs according to histologic subtypes. Raponi et al 27 reported that miR146b is a robust predictor of overall survival in squamous cell carcinoma (SCC). High miR-146b expression correlated with a poor overall survival in SCC patients, and the same trend was also observed in the expression level of miR-155 among the same group of patients. Landi et al 28 identified an miR expression profile that strongly differentiated 165 adenocarcinomas from 125 SCCs and had prognostic implications. A signature consisting of reduced expression of miRNAs let-7e, and miR-34a, -34c-5p, -25, and -191 was found to be prognostic of poor survival among male smokers with stages I to IIIA SCC. These findings may lead to histology-based therapeutic approaches.
Overall, although such correlations between prognosis and miRNA expression have been noted in multiple studies, many of the identified miRNA-based predictors have yet to be independently validated. Moreover, as for gene expression profiling, the miRNA classifiers reported in the different studies are only somewhat overlapping, and this could likely due to the different experimental platforms used (q-RT-PCR vs different miRNA array systems), (pre)analytic approaches, formalin-fixed paraffinembedded versus fresh frozen samples, size of cohorts, and potential ethnic differences in the study populations. More detailed, larger, and independent validation studies are needed to clarify these issues.
PROGNOSTIC SIGNIFICANCE OF MIRNAS IN NORMAL LUNG TISSUES
Lung cancer is essentially a genetic disease affecting epithelial cells, but the influence of the tissue microenvironment on cancer development is gaining increasing attention. In the last decade, several studies have demonstrated strong interactions among stromal components, cells of the immune system, and cancer cells promoting tumor growth, progression, and metastasis. 29 Cancer-associated fibroblasts display protumorigenic features, with ''wound-healing'' myofibroblast traits and a highly activated phenotype. 30 These resident stromal components, likely distorted by carcinogen exposure and chronic obstructive disease and possibly depending on individual genetic variations, are an appealing source of early biomarkers for aggressive lung cancer. Recently, a strong prognostic gene expression signature, validated in independent data sets, was derived from carcinomaassociated fibroblasts in 15 NSCLC samples as compared with matched normal fibroblasts. 31 MicroRNA biomarkers indicating changes in the status of the lung microenvironment could be thus helpful to understand these interactions and to identify diagnostic and prognostic tools.
In a recent article, 9 we explored miRNA expression profiles of lung tumors and normal lung tissues from cases with variable prognosis identified in a completed spiral CT screening trial with extensive follow up. In fact, critical issues for a routine use of CT screening for lung cancer detection still remain the frequency of unnecessary treatments and impact on mortality, indicating the need for biomarkers of aggressive disease.
MicroRNA expression patterns significantly distinguished (i) tumors from normal lung tissues, (ii) tumor histology and growth rate, (iii) clinical outcome, and (iv) year of lung cancer CT detection. The latter analysis was based on the clinical observation of a different survival rate in patients detected in the first 2 years of screening versus those of later years of screening. Our results showed that, both in tumors and also in normal lung tissue samples, miRNA profiles were able to clearly classify patients according to year of CT detection and thus according to tumor aggressiveness, independently from stage and type (Fig. 2) .
The finding of miRNA expression profiles associated with aggressive disease and poor survival in normal lung tissues of the patients strengthens the existing evidence on the critical influence of the normal lung microenvironment on tumor development and on tumor aggressiveness. It is possible to speculate that these markers might represent molecular signs of a ''soil'' that, after extensive damage caused by smoking, becomes permissive or even promoting, for cancer development. The elucidation of the relevance of selected miRNAs in the cross-talk between cancer cells and stromal components could thus lead to the generation of stronger prognostic biomarkers of lung cancer and possible targeted treatments.
CIRCULATING MIRNAS AS LUNG CANCER BIOMARKERS
The cancer biomarkers so far identified that are in clinical use, such as carcinoembryonic antigen for colon cancer, alphafetoprotein associated with hepatocellular carcinoma, and the prostate-specific antigen (PSA) in prostate cancer, have limitations with respect to their use for screening owing to low sensitivity and specificity in early stages and inability to distinguish aggressive from indolent tumors. The recent results of a large trial clearly demonstrate that systematic use of PSA is not only ineffective, but also increases prostate cancer mortality due to harmful treatments applied to an otherwise indolent disease. 32 Other common cancers, such as lung cancer, lack established biomarkers with demonstrated clinical utility in a screening setting. Thus, there is a need for biomarkers with the required sensitivity and specificity for the detection of lung cancer. To overcome the limitation of a single blood-based biomarkers in clinical use, circulating miRNA expression profiles, not single or a couple of miRNAs, that constitute the fingerprint of physiologic or pathological conditions, have the potential to strongly impact on early cancer diagnosis.
STABILITY AND PHYSICAL STATE OF CIRCULATING MIRNA
The first report of circulating miRNAs as stable blood-based markers for cancer detection was published in the second half of 2008 by Mitchell et al. 33 They showed that miRNAs are present in clinical samples of plasma and serum in remarkable stable form, even after repeated freeze-thawing cycles, and may constitute a promising class of blood-based cancer biomarkers. In fact, using a prostate xenograft model system and clinical samples from patients with prostate cancer, they proved that tumorderived miRNAs reach the circulation even when originating from an epithelial cancer type and are able to discriminate prostate cancer versus healthy condition.
Two subsequent articles published in 2011 performed a systematic investigation of the physical state of miRNAs in plasma and serum and provided insight into mechanisms accounting for circulating miRNA stability. Arroyo et al 34 reported that exogenous purified plasma miRNAs were rapidly degraded when incubated in plasma, concluding that circulating miRNAs are not intrinsically resistant to endogenous ribonuclease activity. They found that vesicle-encapsulated miRNAs represent only a minor portion of circulating miRNAs and that the major portion (90%) are present in a nonYmembrane-bound form, associated with ribonucleoprotein complexes, and in particular are loaded in complexes with argonaute 2, the effector component of the miRNA-induced silencing complex that directly binds miRNAs and mediates messenger RNA repression in cells. The same results and conclusions were reached by independent investigators who also indicated that other miRNA complexes may also exist in plasma. 35 Intriguingly, this finding raises the possibility that, being the argonaute 2YmiRNA complexes the core catalytic component of the miRNA silencing complex, these complexes may be purposively released from cells and act in a paracrine manner to regulate gene expression in recipient cells. Thus, circulating miRNAs not merely could represent simple biomarkers of disease but also could be functionally involved in cancer pathogenesis.
CIRCULATING MIRNAS AS DIAGNOSTIC AND PROGNOSTIC BIOMARKERS
In late 2008, Chen et al 36 reported the identification of specific expression patterns of serum miRNAs for lung cancer, colorectal cancer, and diabetes, providing evidence that serum and plasma contain a large amount of stable miRNAs derived from various tissues/organs. The diagnostic value of 2 NSCLCspecific miRNAs (mir-25, -223), identified by Solexa sequencing, was further validated in an independent series of 152 lung cancer patients and 75 healthy donors. Importantly, they also showed that expression levels of serum miRNAs are reproducible and consistent among healthy individuals and that, whereas in healthy subjects miRNAs detected in serum and blood cell fraction are almost overlapping, in lung cancer patients serum miRNAs are different from lung cancer blood cell miRNAs, supporting the conclusion that serum miRNAs are not simply a product from blood cells but also serve as indicators of a disease state and that a unique expression profile of serum miRNAs is associated to each cancer type (i.e., lung and colorectal cancer).
Subsequent studies analyzed circulating miRNA profiles using different approaches that, to some extent, explain their different experimental findings. Some authors used an unbiased high-throughput approach with genome-wide Solexa sequencing or microarrays that led to the identification of 4 miRNAs (mir-486, -30d, -1, and -499) significantly associated with lung cancer survival in 60 patients, 37 further validated in a large series of 243 patients, and of 2 miRNAs (miR-1254 and miR-574-5p) significantly increased in early-stage NSCLC samples using smaller training and validation series 38 ( Table 1 ). The expression levels in plasma or serum of selected miRNAs, identified on the basis of their differential expression in tumor tissues or by isolation of circulating exosomes/vesicles, were analyzed in other studies. These authors reported findings of diagnostic miRNAs, 39, 40 of miRNAs associated with tumor stage and survival, 41 and of miRNAs involved in metastasis and response to therapy 42 (Table 1) . Recently, Shen et al 43 analyzed the expression of 5 miRNAs that they previously found differentially expressed in lung tumors, in subjects with malignant and benign solitary pulmonary nodules (SPNs) and disease-free smokers, an interesting clinical setting. The combination of 3 miRNAs, mir-21, -210, -486-5p, differentiated malignant versus benign SNPs with a suboptimal accuracy degree (76% sensitivity, 85% specificity). Moreover, significantly and even more remarkable abnormal expression of these miRNAs was already found comparing benign SNPs versus disease-free smokers.
As expected, most of these miRNAs are not overlapping in the different studies, likely due to the selection bias of their study design as well as to data normalization methods, because no trustable housekeeping miRNAs circulating in plasma/serum have been found yet and considering that normalization of data using different control miRNAs considerably affects the experimental results.
CIRCULATING MIRNAS AS SCREENING TOOLS
Two recent studies addressed the key question of how early circulating miRNA biomarkers become significant, when a cancer is at its earlier stages or even before a tumor is fully developed. Two authors 9, 44 had the opportunity to study miRNA expression profiles in plasma and serum samples, respectively, collected from individuals enrolled in different LDCT screening trials, with the advantage of measuring changes in circulating miRNAs associated with the very early lung nodules that are identified by spiral LDCT, and also to analyze samples from patients with a diagnosis of benign/indolent pulmonary lesions, a byproduct of overdiagnosis in CT screening studies, as well as from aggressive, fast-growing tumors arising in later years of screening.
Our group, 9 using an high-throughput technology (microfluidic cards containing 378 miRNAs), analyzed plasma samples from 68 lung cancer patients and 88 disease-free controls, divided in training and validation sets, belonging to two independent LDCT screening studies, a completed pilot observational study and an ongoing randomized trial (MILD). We reported miRNA diagnostic signatures able to discriminate lung cancer patients according to their tumor aggressiveness and also by analyzing predisease plasma samples longitudinally collected during the 2 independent CT trials, miRNA signatures identifying those patients whose tumors presented with aggressive clinical behavior, up to 2 years before they were detectable by spiral CT. Sensitivity and specificity of the signatures were high, ranging from 80% to 90% for risk and diagnosis to 90% to 99% for those identifying aggressive lung cancer onset. Of interest, we choose to look at reciprocal levels of miRNAs (miRNA ratios), a method that allowed to bypass the issue of data normalization using controversial ''housekeeping'' miRNAs and that proved to be more informative of the disease status than absolute level of individual miRNAs.
The findings in predisease plasma samples, coupled with the observation, reported in the same article, that miRNA expression profiles not only of incident, fast-growing tumors but also their normal lung counterpart display significant differences as compared with that observed in tissues of patients with indolent, slow-growing lesions further indicate that lung microenvironment is strongly involved in the generation of miRNA signatures of aggressive disease that may be released into the bloodstream and represent powerful risk biomarkers of an organ predisposing to develop lung cancer.
Bianchi et al 44 reported a 34-serum-circulating-miRNA signature, identified using microfluidic cards containing 365 miRNAs, able to identify asymptomatic high-risk individuals with early lung cancer and distinguish malignant lesions from benign nodules revealed by LDCT. They used serum samples from 59 patients with a diagnosis of NSCLC in the first 2 years of the COSMOS LDCT screening study and from 69 individuals who remained disease-free during the entire study as controls, divided in training and testing sets. The risk score derived from the 34 miRNA signature was able to diagnose with 80% accuracy patients versus controls and benign nodules (n = 33). Even if miRNA profiles were obtained in different biological samples (i.e., plasma vs serum), and analysis of data was performed with different methods, there is considerable overlap in the number of miRNAs that consistently circulate in plasma/ serum of smokers, and 10 miRNAs are common in the diagnostic signatures obtained in the 2 studies. These findings, however, need to be validated particularly in term of specificity, a relevant issue when developing a signature for diagnostic anticipation in high-risk individuals, in larger prospective cohorts to establish the real efficacy of a circulating miRNA assay, in combination or even independent from LDCT screening, as diagnostic test for lung cancer detection, with a low cost, nontoxic, and noninvasive procedure. These results have important clinical implications because the use of circulating miRNA profiles could be helpful to reduce the extent of overdiagnosis and consequent unnecessary surgical intervention and overtreatment of low-risk disease, a critical issue inherent to LDCT screening.
CONCLUSIONS
MicroRNAs represent promising biomarkers because for their nature they remain rather intact and stable in fixed tissues and body fluids, are extremely tissue specific, and, being involved in multiple biological pathways, are informative on the molecular pathogenesis of the disease.
Data from the current literature provide evidence that miRNA profiles allow distinction of tumor from normal lung tissue, are able to efficiently classify lung tumor histotypes (i.e., squamous vs adenocarcinoma) and that patterns of altered miRNA expression are consistently associated to clinical outcome, thus representing a useful diagnostic and prognostic tool.
The discovery of circulating miRNAs in plasma and serum offers the opportunity to use them as biomarkers reflecting a particular physiologic or disease state by obtaining a simple blood sample and testing with methodologies, such as q-RT-PCR, easily applicable in a clinical laboratory. Latest studies of circulating miRNA profiling in subjects enrolled in lung cancer screening trials strongly support the integration of miRNA biomarkers to improve the specificity of radiologic imaging to identify the most aggressive forms of lung cancer, opening new perspectives in the early detection and in the management of this lethal disease. 45 
